{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:20:17Z","timestamp":1783948817941,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.schres.2019.07.055","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T17:40:32Z","timestamp":1566927632000},"page":"408-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study"],"prefix":"10.1016","volume":"215","author":[{"given":"Nakao","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishigooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Hyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ku","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Hatim","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena","family":"Cosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Suchkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Agarkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20133","key":"10.1016\/j.schres.2019.07.055_bb0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","article-title":"Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"139","author":"Alvarez-Jimenez","year":"2012","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2019.07.055_bb0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2019.07.055_bb0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/2045125314542098","article-title":"A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections","volume":"4","author":"Das","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.schres.2019.07.055_bb0020","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/656370","article-title":"Second-generation antipsychotics and extrapyramidal adverse effects","volume":"2014","author":"Divac","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"10","key":"10.1016\/j.schres.2019.07.055_bb0025","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/ijnp\/pyx038","article-title":"Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model","volume":"20","author":"Duric","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"21\u221222","key":"10.1016\/j.schres.2019.07.055_bb0030","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1007\/s00213-016-4415-6","article-title":"Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2\/3 receptor occupancy study","volume":"233","author":"Fervaha","year":"2016","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.schres.2019.07.055_bb0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2019.07.055_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/npr2.12057","article-title":"Blonanserin versus haloperidol in Japanese patients with schizophrenia: a phase 3, 8-week, double-blind, multicenter, randomized controlled study","author":"Harvey","year":"2019","journal-title":"Neuropsychopharmacology reports"},{"key":"10.1016\/j.schres.2019.07.055_bb0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2147\/NDT.S59861","article-title":"Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone","volume":"10","author":"Hori","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.schres.2019.07.055_bb0050","first-page":"39","article-title":"Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol","volume":"18","author":"Inada","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2019.07.055_bb0055","first-page":"301","article-title":"Basic studies on the standerdization of patch test","volume":"80","author":"Kawamura","year":"1970","journal-title":"Nippon Hifu Gakkai Zasshi"},{"issue":"2","key":"10.1016\/j.schres.2019.07.055_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088049","article-title":"Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Kishi","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.schres.2019.07.055_bb0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/a-0574-0088","article-title":"Efficacy, tolerability, and safety of blonanserin in schizophrenia: an updated and extended systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Kishi","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2019.07.055_bb0070","author":"Korea Food and Drug Administration"},{"issue":"7","key":"10.1016\/j.schres.2019.07.055_bb0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","volume":"268","author":"Krause","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2019.07.055_bb0080","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/schbul\/sbp046","article-title":"Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature","volume":"35","author":"Kreyenbuhl","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2019.07.055_bb0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/S40037-016-0308-Y","article-title":"Effect size - large, medium, and small","volume":"5","author":"Leppink","year":"2016","journal-title":"Perspect Med Educ"},{"issue":"10","key":"10.1016\/j.schres.2019.07.055_bb0090","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2019.07.055_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpsychires.2015.07.015","article-title":"Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: a double-blind, parallel-group multicenter randomized trial","volume":"69","author":"Li","year":"2015","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.schres.2019.07.055_bb0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02354306","article-title":"A new five factor model of schizophrenia","volume":"65","author":"Lindenmayer","year":"1994","journal-title":"Psychiatr Q"},{"issue":"2","key":"10.1016\/j.schres.2019.07.055_bb0105","first-page":"297","article-title":"Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with risperidone","volume":"11","author":"Miura","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"11","key":"10.1016\/j.schres.2019.07.055_bb0110","first-page":"2059","article-title":"Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with haloperidol","volume":"10","author":"Murasaki","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.schres.2019.07.055_bb0115","author":"Osaka Dainippon Sumitomo Pharma Co., Ltd."},{"issue":"7","key":"10.1016\/j.schres.2019.07.055_bb0120","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0269881108092124","article-title":"Depot and oral antipsychotics: patient preferences and attitudes are not the same thing","volume":"23","author":"Patel","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2019.07.055_bb0125","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2019.07.055_bb0130","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00228-010-0834-1","article-title":"Effect of dose timing in relation to food intake on systemic exposure to blonanserin","volume":"66","author":"Saruwatari","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.schres.2019.07.055_bb0135","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.biopsych.2013.11.023","article-title":"Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition","volume":"76","author":"Simpson","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2019.07.055_bb0140","series-title":"New Drug Application in Japan for Transdermal Patch Formulation of Atypical Antipsychotic LONASEN\u00ae","author":"Sumitomo Dainippon Pharma Co., Ltd.","year":"2018"},{"issue":"6","key":"10.1016\/j.schres.2019.07.055_bb0145","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ijnp\/pyy004","article-title":"Comparison of dopamine D3 and D2 receptor occupancies by a single dose of blonanserin in healthy subjects: a positron emission tomography study with [11C]-(+)-PHNO","volume":"21","author":"Tateno","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2019.07.055_bb0150","first-page":"1263","article-title":"Pharmacological profile of blonanserin","volume":"10","author":"Une","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.schres.2019.07.055_bb0155","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/PPA.S124658","article-title":"Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness","volume":"11","author":"Velligan","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"10.1016\/j.schres.2019.07.055_bb0160","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","article-title":"Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia","volume":"55","author":"Weiden","year":"2004","journal-title":"Psychiatr. Serv."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419303354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:39:08Z","timestamp":1760297948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996419303354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":32,"alternative-id":["S0920996419303354"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2019.07.055","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2019.07.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}